Patent intelligence · US
US 12263179
Lyme disease-associated T cell receptor-related methods
Lyme disease-associated T cell receptor-related methods
Patent details — US 12263179
- Jurisdiction
- US
- Status
- granted
- Grant date
- Apr 1, 2025
- Expiration
- Mar 27, 2045
- Applicant
- Adaptive Biotechnologies Corporation
- Claims
- 10
- CPC classes
- A61K, A61K31/43, A61K31/431, A61K31/53
Quick answer
US 12263179 (Lyme disease-associated T cell receptor-related methods) is held by Adaptive Biotechnologies Corporation. Status: granted. Granted Apr 1, 2025. Expires Mar 27, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Adaptive Biotechnologies Corporation
- Grant date
- Expiration
- Claims
- 10
- CPC classes
- A61K, A61K31/43, A61K31/431, A61K31/53, A61K31/546, A61K31/65
More from Adaptive Biotechnologies Corporation
Related pharmaceutical patents in our USPTO index.
-
US 12264187
Compositions and methods for targeted therapeutic delivery to bone
granted -
US 12266425
T cell receptor sequences diagnostic for COVID-19 and related compositions
granted -
US 12006517
Method for purification of bacteriophage particles
granted -
US 11911345
Phage dispensing system
granted -
US 11773138
Polypeptides including a beta-tricalcium phosphate-binding sequence and uses thereof
granted -
US 11390921
Determining WT-1 specific T cells and WT-1 specific T cell receptors (TCRs)
granted -
US 11192923
Polypeptides including a beta-tricalcium phosphate-binding sequence and uses thereof
granted
Frequently asked questions
What is US patent 12263179?
US 12263179 (Lyme disease-associated T cell receptor-related methods) is held by Adaptive Biotechnologies Corporation. Status: granted. Granted Apr 1, 2025. Expires Mar 27, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12263179?
Adaptive Biotechnologies Corporation is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 12 pharmaceutical patents for this assignee.
When does US 12263179 expire?
Our index shows an expiration date of Mar 27, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.